Spots Global Cancer Trial Database for INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Official Title: A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Study ID: NCT03589651
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinic and Research Institute, Los Angeles, California, United States
Yale New Haven Hospital, New Haven, Connecticut, United States
University of Florida - Shands Cancer Center, Gainesville, Florida, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Rutgers Cancer Institute of Nj, New Brunswick, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
